3 psoriasis cases show why escalation cannot rest on BSA alone
![<![CDATA[Experts Discuss Personalized Treatment Strategies for Psoriasis]]>](/media/b6/b6e5941d3dac3ad5.1280.webp)
By Sophie Lindqvist
Three patient cases presented at a Dermatology Times Case-Based Roundtable in New York City showed that plaque psoriasis escalation cannot rest on body surface area (BSA) alone. Christopher Bunick, MD, PhD, a dermatologist at Yale School of Medicine and Dermatology Times editor-in-chief, led the clinical discussion across 3 illustrative cases.
The group examined when to move beyond topical therapy, how to select a biologic for patients with complex medical histories, and how to match long-term regimens to work routines and self-care capacity. The meeting also took place as the range of systemic therapies continued to expand, making feasibility and persistence central rather than optional details.
The roundtable’s stated takeaway was explicit: “Treatment escalation should incorporate functional impairment, treatment burden, and occupational feasibility, not BSA alone, particularly when topical adherence is intrinsically impractical.”
Case 1 and cardiovascular risk
Case 1 involved a 39-year-old roofing contractor with an 8-year history of plaque psoriasis affecting approximately 15% of BSA, mainly across his trunk and arms. Sweating, sun exposure and friction from work equipment worsened symptoms. His medical history included obesity, hypertension and a family history of premature coronary artery disease.
His previous topical corticosteroid use lacked consistency, and he had received neither systemic nor biologic therapy. Participants cited the 15% BSA burden, inadequate control with topicals and the practical difficulty of applying medication outdoors as reasons to escalate. They also weighed his occupational exposure, treatment preferences and comorbidities when choosing systemic therapy.
Bunick directed the group toward psoriasis as a systemic inflammatory disease, particularly in someone with existing cardiovascular risk factors. The discussion exposed the limits of topical corticosteroids when disease severity and application burden make them impractical, and it placed the potential consequences of prolonged uncontrolled disease alongside the escalation decision.
Case 2 and the burden of a daily routine
Case 2 centered on a 72-year-old retired school administrator with plaque psoriasis affecting approximately 12% of BSA, primarily at her elbows, knees and lower back. Pruritus disrupted sleep and daily activities, while knee plaques contributed to difficulty walking. Her history included hand osteoarthritis and medically controlled type 2 diabetes.
She had previously received topical corticosteroids and roflumilast. Arthritis made topical application difficult, and she struggled to maintain a consistent oral medication routine. Participants considered her age, functional limitations and independent living when weighing less frequent dosing and health care professional-administered treatment.
Extended-maintenance biologics, including tildrakizumab, offered a possible route to lower treatment burden. One clinician proposed scheduling office visits every 12 weeks for medication administration, which could support adherence while maintaining regular contact with the care team. The discussion also considered treatment persistence among older adults and the role of office-based administration.
The practical result was not a dismissal of efficacy. It was a recognition that convenience and accessibility can matter as much as efficacy when clinicians build a plan a patient can sustain.
Case 3 after 6 months of secukinumab
The third case involved a 34-year-old emergency department nurse with plaque psoriasis affecting approximately 50% of BSA, including her scalp and fingernails. Diagnosed at age 28, she had progressive disease despite intermittent topical corticosteroid use and 6 months of secukinumab, an interleukin-17A inhibitor.
Her rotating 12-hour days and overnight shifts complicated adherence, while irregular sleep and the physical demands of her job appeared to coincide with disease flares. Anxiety and migraines added to the psychosocial burden. Participants weighed the implications of inadequate secukinumab response alongside the difficulty of managing extensive psoriasis.
They considered switching within the IL-17 inhibitor class or changing mechanisms of action, including IL-23 inhibition. Scalp and nail involvement prompted review of efficacy data in those difficult-to-treat areas and discussion of how disease extent and location might influence drug selection.
Because she worked at the same hospital as the dermatology practice, office-administered injections could accommodate her unpredictable schedule and reduce the burden of self-administration. The case reinforced reassessing both treatment efficacy and feasibility when disease control remains inadequate.
Shared decisions, unequal constraints
Across the 3 cases, participants repeatedly returned to shared decision-making and individualized treatment selection. Although biologic efficacy remained central, the clinicians’ practical formulation was direct: “Treatment success also depends on whether patients can realistically maintain a prescribed regimen.” Injection frequency, administration setting, insurance requirements, occupational demands and functional limitations all influenced persistence.
Bunick also urged participants to consider psoriasis within the broader relationship between chronic inflammation and cardiovascular disease. In the first patient, obesity, hypertension and a family history of premature coronary artery disease supported earlier systemic therapy consideration.
During the closing discussion, he highlighted the need for additional cardiovascular outcomes data to determine whether psoriasis interventions change long-term cardiovascular risk.
What does this change for psoriasis care?
It changes the sequence and content of the decision. Clinicians should assess disease severity and location, comorbidities, treatment history, functional impairment, work demands, administration burden, insurance requirements and patient preferences, then test whether the proposed regimen can be maintained in the patient’s actual daily life.
For the 72-year-old administrator, less frequent dosing and 12-week office administration were central. For the nurse with 50% BSA disease, scalp and nail involvement, IL-23 inhibition and delivery during unpredictable shifts shaped the discussion. For the roofing contractor, cardiovascular risk, outdoor application difficulty and systemic treatment preferences drove escalation.
Skin clearance remains the central efficacy goal, but the cases show why BSA cannot stand alone. They also leave the cardiovascular question open: these discussions cannot establish whether treating psoriasis lowers cardiovascular risk. The forward-looking step is individualized, sustainable therapy aimed at meaningful disease control, paired with the cardiovascular outcomes research Bunick called for.
Source: dermatologytimes.com
Sophie Lindqvist
Show full bio
Market editor covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.